Anthropic reports early progress on using Claude to accelerate drug development

Anthropic's life sciences team has spent several months working with six drug developers, including Bristol Myers Squibb, Generate Biomedicines and Divergence Labs, plus running its own discovery programs, to test where Claude can speed up drug development. Reported early results include a Generate design roughly 70% shorter than the standard version that let immune cells make about 10 times as many receptors, and roughly 35,000 antibody designs generated largely autonomously for Divergence in about a month. Anthropic says the work is still mostly preclinical and plans to extend Claude into clinical trials as the programs advance.